Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer

Trial Profile

Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Aug 2017 to 9 Aug 2019.
    • 18 Apr 2017 Planned primary completion date changed from 1 Aug 2016 to 9 Aug 2018.
    • 23 Jun 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top